Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-04-08

Clinical Trial Update: Empagliflozin add-on to Insulin in Type 1 Diabetes Mellitus Over 28 Days [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating empagliflozin added to insulin in adults with Type 1 diabetes mellitus over 28 days; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Empagliflozin (empagliflozin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Diabetes Mellitus, Type 1 | Phase 2 | Status: COMPLETED | Results posted: 2015-04-08